Albert Bourla (Evan Vucci, AP Images)

Covid-19 roundup: Pfiz­er/BioN­Tech say boost­er is 95.6% ef­fec­tive; Eu­ro­pean Par­lia­ment calls for more vac­cine trans­paren­cy

A month af­ter the FDA au­tho­rized a boost­er dose of Pfiz­er and BioN­Tech’s Covid-19 shot for cer­tain at-risk in­di­vid­u­als, the com­pa­nies are re­leas­ing new da­ta that sug­gest the ex­tra shot has a 95.6% ef­fi­ca­cy com­pared to the two-dose se­ries.

The re­sults come from a Phase III tri­al that test­ed a third 30 µg dose of the vac­cine giv­en at a me­di­an of 11 months, com­pared to a place­bo on top of Pfiz­er’s two-dose se­ries. A thou­sand par­tic­i­pants 16 years and old­er par­tic­i­pat­ed, just over 23% of whom were 65 or old­er.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.